Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v1-EN
Language French English
Date Updated 2025-11-19 2025-06-16
Drug Identification Number 01926829 01926829
Brand name FLAGYSTATIN FLAGYSTATIN
Common or Proper name Flagystatin Ovules Flagystatin Ovules
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients METRONIDAZOLE NYSTATIN METRONIDAZOLE NYSTATIN
Strength(s) 500MG 100000UNIT 500MG 100000UNIT
Dosage form(s) OVULE SUPPOSITORY OVULE SUPPOSITORY
Route of administration VAGINAL VAGINAL VAGINAL VAGINAL
Packaging size 10 10
ATC code G01AA G01AA
ATC description ANTIINFECTIVES/ANTISEPT.,EXCL COMB WITH CORTICOST. ANTIINFECTIVES/ANTISEPT.,EXCL COMB WITH CORTICOST.
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2025-06-16 2025-06-16
Actual start date 2025-06-16 2025-06-16
Estimated end date Unknown Unknown
Actual end date 2025-11-18
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Supply delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. Supply delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments